As we move into the fall, I’ve been thinking a lot about what it really takes to turn the promise of drug repurposing into impact for patients. Identifying a promising new use for an existing medicine is an incredibly important first step, but it’s only the beginning. At Every Cure, our goal is to see […]

Last month marked four years since we started Every Cure in August 2022, and we are so thankful for all of the impact that we’ve been able to make together. When we started Every Cure, we had an ambitious idea: build a nonprofit that could systematically identify new uses for existing medicines and help advance […]

One of the most rewarding parts of our work at Every Cure is seeing years of scientific collaboration translate into meaningful progress for patients. This month, we’re excited to share one of those moments. The National Comprehensive Cancer Network (NCCN) recently updated its treatment guidelines for a debilitating rare disease called Rosai-Dorfman disease (RDD), elevating […]

We’re excited to share that Every Cure recently launched three new drug repurposing programs to help patients with devastating diseases that have few treatment options. One of those programs focuses on a rare mitochondrial disease primarily affecting children and young adults and has no FDA-approved therapies. It’s one of many diseases where we believe drug […]

Thank you for your continued support of our mission. In addition to sharing important updates this month, we’re excited to share that we now have a place where you can indicate specific diseases that you’re interested in receiving targeted updates about. You can sign up here, and we’ll be in touch if/when we have updates […]

We’re so pleased to highlight two important publications that build upon and reinforce our mission. In one, we worked with partners to evaluate a promising treatment for a rare disorder called Rosai-Dorfman-Destombes disease, which is one of our 10 active drug repurposing programs. In the other, we introduced a new way to measure which diseases […]

In this newsletter, we’ll highlight the progress we’re making — for patients like Jameson, with partners like ARPA-H, and with supporters like Giorgos Tsetis — and show why this work matters. Thank you for being part of this journey with us.